Overall, these results show that SC144@HABN + anti-PD-L1 combo therapy increased the frequency of tumor-infiltrating CD8+ T-cells and the ratio of M1/M2 macrophages in the TME while decreasing CD4+ Tregs, leading to robust anti-tumor efficacy and establishment of long-term anti-tumor immunity. This evidence concerns the gene CD8A and neoplasm.